glp 1 coverage 2026 Medicare GLP-1 2026: The $50 Copay, The Delay, and What Comes Next GLP-1 Clinical Practice Updates: February

"We expected, I think, a more pronounced change, but our results were pretty similar," Maya said

It is essential to distinguish between gastric emptying delayan expected pharmacologic effect that typically attenuates with continued therapyand true gastroparesis, which implies persistent, clinically significant gastric dysfunction

Widely used for type 2 diabetes mellitus and obesity, glucagon-like peptide-1 receptor agonists (GLP-1RAs) may increase risk for injection-site reactions, especially exenatide and dulaglutide (Trulicity, Eli Lilly)

Rather, it is more probable that the weight loss yielded by treatment with these drugs may induce intrinsic physiologic and hormonal changes that induce or exacerbate acne vulgaris in such patients. The study did have its share of limitations

In the SURMOUNT-1 trial, tirzepatide produced dose-dependent weight reductions, with average losses approaching or exceeding ~20% at higher doses in adults with obesity who did not have diabetes, numbers that markedly exceed historical pharmacotherapy benchmarks